Cookies and the protection of your data

We use cookies to improve the functionality of the website, to offer you a better website experience and to provide social media features. You give your consent by clicking on “Accept all Cookies” or as part of your individual settings. Please find detailed information on the use of cookies on this website in our Data Privacy Statement.

Functional Cookies

These cookies are necessary for the operation of the site and enable security-relevant functions. In addition, we determine whether you want to remain logged in and to make our services available to you when you change between this and other websites.

Statistical Cookies

These cookies are used for analyzing user behavior on our website with the aim of improving user navigation. All data collected is evaluated anonymously. Further information is available on our data protection site.

Marketing Cookies

These cookies are used to deliver relevant advertising or to limit how many times you see an ad. Marketing cookies can share that information with the advertiser (third-party cookies). The legal basis for the data processing is the consent of the user.

dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
dermaject
2018

Share:

dermaject

Injection device

Dermaject is a specialty drug delivery device for the injection of liquid drugs, such as therapeutic cancer treatments into the upper layer of the skin (the dermis, just below the skin surface). Most intradermal (i.d.) injections are carried out manually with painful thick needles and an error rate of about 20%. Dermaject standardizes injections, reduces errors, is 2 times faster and, thanks to a needlestick injury shield, is far less painful. Intradermal injections using dermaject exhibit up to 30x increased efficacy compared to the normal subcutaneous route. It is also the only device mimicking the Mantoux method of sharp angle entry.

Client / Manufacturer

Hahn-Schickard

Villingen-Schwenningen, DE
Verapido Medical GmbH

Verapido Medical GmbH

Villingen-Schwenningen, DE
Design
Verapido Medical GmbH

Verapido Medical GmbH

Villingen-Schwenningen, DE
Date of Launch
2017
Development Time
25 - 36 months
Target Regions
Asia, Australia/Oceania, Europe, North America
Target Groups
Trade / Industry, Specific sub-group: Pharma

RELATED PROJECTS